NanoViricides, Inc. (NYSEMKT:NNVC)

CAPS Rating: 1 out of 5

Results 1 - 13 of 13

Recs

0
Member Avatar pchop12316 (68.99) Submitted: 12/14/2014 7:42:28 PM : Underperform Start Price: $2.81 NNVC Score: -8.28

need lots to impress

Recs

0
Member Avatar jed71 (90.50) Submitted: 12/12/2014 12:14:16 PM : Underperform Start Price: $2.81 NNVC Score: -8.28

You can call me a skeptic all you want, but I just don’t trust reverse mergers that used to be internet retail companies, no matter how legitimate they try to make themselves in their recent past. I can’t help but feel their “pipeline” of 7 drug candidates is about as valuable as a set of patents for manufacturing a buggy whip from the 1850’s. Here are the sections from the most recent 10-Q that convinced me to down thumb:

“NanoViricides, Inc. was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc. which was organized for the purpose of conducting internet retail sales. On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation. On May 12, 2005, the corporations were merged and Edot-com.com, Inc., the Nevada corporation, became the surviving entity.”

“As a result of the Exchange transaction, the former NVI stockholders held approximately 80% of the voting capital stock of the Company immediately after the Exchange. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.”
“On February 15, 2010 the Company executed an Additional License Agreement with TheraCour Pharma, Inc. (“TheraCour”). Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).”

“On or about April 13, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-659535-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”). The Complaint seeks to compel inspection of the Company’s books and records. On or about May 2, 2012, the Company filed a Demand for Security of Costs.”

Zero revenue company with only some cash as assets. As of last count, about $41MM in cash. Take another look and that last cut and paste: a lawsuit to force the company to open its accounting books for inspection. I am not sure there’s a larger red flag than this. You have to go read the entire entry in the 10-Q, but essentially, they paid the plaintiffs $150K to make it go away. There is normally much more to the story when someone takes this kind of action. Couple this with the reverse merger and previous business plan and this seems to be another great red thumb. I would personally AVOID this firm.

Recs

0
Member Avatar Allstar13913 (99.84) Submitted: 9/11/2014 10:12:45 PM : Underperform Start Price: $3.86 NNVC Score: +22.09

Uses stock pump and dump promoter Redchip.com for PR. Garbage.

Recs

0
Member Avatar adi101 (84.51) Submitted: 3/2/2014 7:49:18 AM : Outperform Start Price: $3.98 NNVC Score: -32.88

nano mechanism that gets VIRUS to attach to (decoy) and then encapsulates it and brakes it. this might pan out as the first virus "antibiotic". as the elimination system is based on the contagion system, there will be no more mutation problem. made of Polyethylene glycol - non toxic. operates OUT OF HUMAN CELLS.

virus account for 80 billion $ sales. most are in effective.

flue is first target.

one in a life time bet.

grateful I found this one.

Recs

0
Member Avatar carsondyle (81.38) Submitted: 2/15/2014 8:02:50 AM : Outperform Start Price: $4.81 NNVC Score: -47.53

Bought this one some time ago as speculative stock before it was on Fool, significant gains so far even with this latest sell off. Still holding, can you imagine what an affective antiviral would be worth? Also like QFOR as part of speculative portion of portfolio.

Recs

0
Member Avatar zincfinger (< 20) Submitted: 11/16/2013 5:50:42 PM : Outperform Start Price: $5.40 NNVC Score: -55.59

Outstanding animal data, no indications of toxicity

does not depend on host immune system (or metabolism) for its effect (impairment of the immune system by virus (or preexisting) have no effect)

approach is inherently deeply resistant to virus mutating around it (the major reason why most antivirals are so ineffective)

very broad spectrum.

Recs

0
Member Avatar 085701 (33.02) Submitted: 9/25/2013 9:22:38 PM : Outperform Start Price: $5.59 NNVC Score: -59.38

this stock is solely a bet on the efficacy of their antiviral drugs. if it doesn't work, this stock will go way down. If it works, it will go way up. lots of people ( and governments ) would pay good money for an effect therapy for dengue.

Recs

0
Member Avatar Dreadz34 (47.41) Submitted: 9/25/2013 7:59:39 PM : Outperform Start Price: $2.13 NNVC Score: +16.17

This stock has sky rocketed.. well over 200% and still climbing if you haven't green thumbed this stock your missing the boat.

Recs

1
Member Avatar AnsgarJohn (98.11) Submitted: 5/28/2013 7:20:45 AM : Underperform Start Price: $2.31 NNVC Score: -10.80

Via penny stock website. Book value 8 cents per stock, no revenue, no profit.

Recs

0
Member Avatar PeterLeyssens (< 20) Submitted: 10/18/2011 4:07:03 PM : Outperform Start Price: $3.15 NNVC Score: -68.38

bet for a stock option

Recs

0
Member Avatar BuffettJunior1 (97.66) Submitted: 5/4/2011 4:36:30 PM : Underperform Start Price: $4.72 NNVC Score: +86.16

Too easy!

Recs

1
Member Avatar kevin939516 (48.05) Submitted: 3/1/2011 6:45:09 PM : Outperform Start Price: $4.86 NNVC Score: -91.85

Sole developer of technology that can be used to teat and/or prevent any viral infection. Yes, they are still in production of this technology, but they've had alot of promisingresearch lately. Additional bonus: it is not a vaccine so it will not take years to be approved, and the FDA seems to be giving signs that they look forward to it.

Recs

1
Member Avatar LorenCobb (68.57) Submitted: 3/29/2010 2:35:17 PM : Outperform Start Price: $6.05 NNVC Score: -121.93

This tiny company is the sole developer of a unique and extremely promising nanotech approach to the creation of new vaccines. They have under development vaccines for all forms of influenza, HIV, hepatitis C, rabies, and dengue fever. I have followed them for the past three years, with growing conviction that they have what it takes.

Results 1 - 13 of 13

Featured Broker Partners


Advertisement